Fluid-Based Biomarkers of Alzheimer’s Disease

Natalia P. Rocha; Antonio L. Teixeira; Leonardo Cruz de Souza

doi:10.1007/978-3-031-43356-6_10

Fluid-Based Biomarkers of Alzheimer’s Disease

Natalia P. Rocha
, Antonio L. Teixeira
, Leonardo Cruz de Souza

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Alzheimer’s disease (AD) is the most common type of dementia, whose incidence is expected to increase drastically due to population aging. The early diagnosis of AD is of utmost importance because of the irreversible nature of the related neuropathological damage. Decreased levels of amyloid-beta 42 (Aβ42) and elevated levels of total tau and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) or positive positron-emission tomography (PET) amyloid imaging have been included in the latest AD diagnostic criteria to increase its reliability. Less costly and less invasive biomarkers would facilitate the use of such markers in clinical practice. In this regard, blood-based biomarkers have been tested, and Aβ and tau (and its phosphorylated isoforms), in addition to neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), hold promise as blood-derived biomarkers for AD.

Original language	English (US)
Title of host publication	Biomarkers in Neuropsychiatry
Subtitle of host publication	A Primer
Publisher	Springer International Publishing
Pages	153-161
Number of pages	9
ISBN (Electronic)	9783031433566
ISBN (Print)	9783031433559
DOIs	https://doi.org/10.1007/978-3-031-43356-6_10
State	Published - Jan 1 2024
Externally published	Yes

ASJC Scopus subject areas

General Medicine
General Neuroscience
General Psychology

Access to Document

10.1007/978-3-031-43356-6_10

Cite this

@inbook{a4c0dd1bb9944ac281849084779a8e07,

title = "Fluid-Based Biomarkers of Alzheimer{\textquoteright}s Disease",

abstract = "Alzheimer{\textquoteright}s disease (AD) is the most common type of dementia, whose incidence is expected to increase drastically due to population aging. The early diagnosis of AD is of utmost importance because of the irreversible nature of the related neuropathological damage. Decreased levels of amyloid-beta 42 (Aβ42) and elevated levels of total tau and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) or positive positron-emission tomography (PET) amyloid imaging have been included in the latest AD diagnostic criteria to increase its reliability. Less costly and less invasive biomarkers would facilitate the use of such markers in clinical practice. In this regard, blood-based biomarkers have been tested, and Aβ and tau (and its phosphorylated isoforms), in addition to neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), hold promise as blood-derived biomarkers for AD.",

author = "Rocha, \{Natalia P.\} and Teixeira, \{Antonio L.\} and \{de Souza\}, \{Leonardo Cruz\}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.",

year = "2024",

month = jan,

day = "1",

doi = "10.1007/978-3-031-43356-6\_10",

language = "English (US)",

isbn = "9783031433559",

pages = "153--161",

booktitle = "Biomarkers in Neuropsychiatry",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Fluid-Based Biomarkers of Alzheimer’s Disease

AU - Rocha, Natalia P.

AU - Teixeira, Antonio L.

AU - de Souza, Leonardo Cruz

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Alzheimer’s disease (AD) is the most common type of dementia, whose incidence is expected to increase drastically due to population aging. The early diagnosis of AD is of utmost importance because of the irreversible nature of the related neuropathological damage. Decreased levels of amyloid-beta 42 (Aβ42) and elevated levels of total tau and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) or positive positron-emission tomography (PET) amyloid imaging have been included in the latest AD diagnostic criteria to increase its reliability. Less costly and less invasive biomarkers would facilitate the use of such markers in clinical practice. In this regard, blood-based biomarkers have been tested, and Aβ and tau (and its phosphorylated isoforms), in addition to neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), hold promise as blood-derived biomarkers for AD.

AB - Alzheimer’s disease (AD) is the most common type of dementia, whose incidence is expected to increase drastically due to population aging. The early diagnosis of AD is of utmost importance because of the irreversible nature of the related neuropathological damage. Decreased levels of amyloid-beta 42 (Aβ42) and elevated levels of total tau and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) or positive positron-emission tomography (PET) amyloid imaging have been included in the latest AD diagnostic criteria to increase its reliability. Less costly and less invasive biomarkers would facilitate the use of such markers in clinical practice. In this regard, blood-based biomarkers have been tested, and Aβ and tau (and its phosphorylated isoforms), in addition to neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), hold promise as blood-derived biomarkers for AD.

UR - https://www.scopus.com/pages/publications/85196110168

UR - https://www.scopus.com/pages/publications/85196110168#tab=citedBy

U2 - 10.1007/978-3-031-43356-6_10

DO - 10.1007/978-3-031-43356-6_10

M3 - Chapter

AN - SCOPUS:85196110168

SN - 9783031433559

SP - 153

EP - 161

BT - Biomarkers in Neuropsychiatry

PB - Springer International Publishing

ER -

Fluid-Based Biomarkers of Alzheimer’s Disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this